Aushon Biosystems said this week that it has signed an exclusive distribution agreement with Fisher Scientific – part of Thermo Fisher Scientific – for North American distribution of Aushon's full line of multiplex immunoassay products and services.
Aushon's offerings include its new SignaturePlus multiplexing system, as well as a kit menu of more than 300 protein biomarker assays, analysis software, and CLIA lab services.
The company's multiplex platform has recently been used in several late-stage clinical trials, including phase II and phase III trials led by researchers at the University of Texas MD Anderson Cancer Center investigating protein biomarkers for predicting patient response to the GlaxoSmithKline kinase inhibitor pazopanib.
“We are very pleased that Fisher Scientific has entered this strategic partnership with Aushon, highlighting the potential for our multiplex immunoassay platform in this high growth market,” Joe Blanchard, Aushon's chief business officer, said in a statement. “This partnership will complement our direct sales team and enable us to access the broadest number of scientists in the North American life science community.”